2. Search Result
Search Result
Results for "

SPAS

" in MedChemExpress (MCE) Product Catalog:

32

Inhibitors & Agonists

1

Biochemical Assay Reagents

4

Peptides

1

Inhibitory Antibodies

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15192
    GSK 650394
    Maximum Cited Publications
    26 Publications Verification

    		 SGK Influenza Virus Infection Cancer
    GSK 650394 is a novel SGK inhibitor with IC50 of 62 nM and 103 nM for SGK1 and SGK2 in the SPA assay respectively. GSK 650394 also inhibits influenza virus replication.
    GSK 650394
  • HY-P2093
    S961
    5+ Cited Publications

    		 Insulin Receptor Metabolic Disease
    S961 is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively .
    S961
  • HY-156112
    LM2I

    		Ser/Thr Protease Cancer
    LM2I is a derivative of Spinosyn A (SPA). LM2I is argininosuccinate synthase (ASS1) enzyme activator, and tumor inhibitor that directly interact with ASS1. LM2I has significant antiproliferative activity in seven colorectal cancer cell-lines and xenograft tumors of colorectal cancer. LM2I inhibits colorectal cancer cell growth via the EGFR pathway .
    LM2I
  • HY-NP006
    Protein A
    1 Publications Verification

    SPA

    		 Endogenous Metabolite Apoptosis Inflammation/Immunology
    Protein A (SPA) is an immunoglobulin (Ig)-binding protein that exists on the bacterial surface and can be freely secreted into the extracellular environment. Protein A blocks opsonophagocytosis and induces B cell apoptosis in vitro by binding to the Fc region of antibodies and the Fab region of B cell receptors. Protein A can form toxic immune complexes with IgG, thereby inducing leukocyte necrosis. Protein A contributes to the virulence expression of Staphylococcus aureus. Protein A triggers allergic reactions in IgG-pretreated mouse models. Protein A can be used in studies related to immune system diseases .
    Protein A
  • HY-P2093B
    S961 acetate
    5+ Cited Publications

    		 Insulin Receptor Metabolic Disease
    S961 acetate is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively .
    S961 acetate
  • HY-10898
    SB-674042
    2 Publications Verification

    		 Orexin Receptor (OX Receptor) Neurological Disease Endocrinology
    SB-674042 is a potent and selective non-peptide orexin OX1 receptor antagonist (Kd=5.03 nM), exhibits 100-fold selectivity for OX1 over OX2 receptors with IC50 values of 3.76 nM and 531 nM, respectively .
    SB-674042
  • HY-124830
    SPA70
    1 Publications Verification

    		 Others Cancer
    SPA70 is a potent and selective antagonist of human pregnane X receptor (hPXR), with an IC50 of 540 nM (Ki=390 nM). SPA70 can enhance the chemosensitivity of cancer cells .
    SPA70
  • HY-135127
    Dot1L-IN-4
    1 Publications Verification

    		 Histone Methyltransferase Cancer
    Dot1L-IN-4 is a potent disruptor of telomeric silencing 1-like protein (DOT1L) inhibitor with an IC50 SPA DOT1L of 0.11 nM .
    Dot1L-IN-4
  • HY-148860
    NVP-DFF332

    HIF-2α-IN-8

    		 HIF/HIF Prolyl-Hydroxylase Cancer
    HIF-2α-IN-8 is a potent and orally active HIF2α inhibitor with IC50 values of 9, 37, 246 nM for HIF2α SPA, HIF2α iScript, HIF2α HRE RGA, respectively. HIF-2α-IN-8 shows antitumor activity .
    NVP-DFF332
  • HY-176293
    EP2 receptor antagonist-3

    		Prostaglandin Receptor Amyloid-β Neurological Disease
    EP2 receptor antagonist-3 is a selective EP2 receptor antagonist (IC50: 8 nM in hEP2 SPA assay, 50 nM in hEP2 cAMP assay). EP2 receptor antagonist-3 increases the macrophage-mediated clearance of Amyloid-β plaques. EP2 receptor antagonist-3 can be used for the study of alzheimer’s diseases .
    EP2 receptor antagonist-3
  • HY-19949
    HIF-2α-IN-1
    1 Publications Verification

    		 HIF/HIF Prolyl-Hydroxylase Metabolic Disease
    HIF-2α-IN-1 (compound 9b) is a HIF-2α inhibitor (IC50=1.7 μM, SPA/scintillation proximity assay) .
    HIF-2α-IN-1
  • HY-168878
    EP652

    		METTL3 Cancer
    EP652 is a METTL3 inhibitor and antitumor agent with IC50 values of 2 nM, <10 nM, and 37 nM in SPA, intracellular, and ATPlite assays, respectively. EP652 exhibits high selectivity against 40 other methyltransferases and FTO, and possesses favorable pharmacokinetic parameters. EP652 reduces intracellular N 6-methyladenosine (m 6A) levels in mRNA. EP652 inhibits tumor growth and progression of both hematologic malignancies and solid tumors. EP652 can be used for the research of acute myeloid leukemia, ovarian cancer, non-small cell lung cancer, and hypopharyngeal squamous cell carcinoma .
    EP652
  • HY-P99770
    Omodenbamab

    514-G3

    		 Bacterial Infection
    Omodenbamab is an anti-SpA (Staphylococcal protein A) human monoclonal antibody with a KD value of 0.0467 nM. Omodenbamab circumvents a key S. aureus evasion mechanism by targeting the cell wall moiety Protein A (SpA). Omodenbamab can be used in research of S. aureus bloodstream infection .
    Omodenbamab
  • HY-118917
    VX-148

    		IMPDH Inflammation/Immunology
    VX-148 is an orally active immunosuppressant, which is a non-competitive inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor with Ki values for IMPDH Ⅱ and IMPDH Ⅰ of 6 and 14 nM respectively. VX-148 can significantly inhibit the proliferation of human peripheral blood mononuclear cells (PBMC) stimulated by T-cell mitogen (PHA) or B-cell mitogen (SPAS). VX-148 has high selectivity for lymphocytes (such as L1210, Jurkat T cells, and Raji B cells), but has no significant toxicity to non-lymphoid cells. VX-148 can inhibit antibody responses in mouse models and significantly prolong the survival time of transplanted skin in allogeneic skin transplantation models. VX-148 can be used in the research of autoimmune diseases (such as rheumatoid arthritis, psoriasis) and organ transplantation anti-rejection .
    VX-148
  • HY-15192R
    GSK 650394 (Standard)

    		SGK Influenza Virus Infection Cancer
    GSK 650394 (Standard) is the analytical standard of GSK 650394. This product is intended for research and analytical applications. GSK 650394 is a novel SGK inhibitor with IC50 of 62 nM and 103 nM for SGK1 and SGK2 in the SPA assay respectively. GSK 650394 also inhibits influenza virus replication.
    GSK 650394 (Standard)
  • HY-19614
    BMS-795311

    		CETP Cardiovascular Disease
    BMS-795311 is a potent and orally bioavailable inhibitor of cholesteryl ester transfer protein (CETP), with IC50s of 4 nM in an enzyme-based scintillation proximity assay (SPA) and 0.22 μM in a human whole plasma assay (hWPA), respectively .
    BMS-795311
  • HY-169703
    SPA0355
    1 Publications Verification

    		 RANKL/RANK p38 MAPK Akt NF-κB Inflammation/Immunology
    SPA0355 is a thiourea derivative that has antioxidant and anti-inflammatory properties. SPA0355 inhibits the RANKL (receptor activator of nuclear factor κB ligand) induced osteoclast formation in primary bone marrow-derived macrophages. SPA0355 also suppresses the activation of the MAPKs, Akt, and NF-κB pathways. Additionally, SPA0355 promotes osteoblast differentiation, increases alkaline phosphatase activity, and enhances mineral nodule formation. SPA0355 can protect ovariectomized mice from bone loss by stimulating osteoblast differentiation and inhibiting osteoclast resorption, making it useful for studying postmenopausal osteoporosis .
    SPA0355
  • HY-P10354
    SPA4

    		Interleukin Related Inflammation/Immunology
    SPA4 is a TLR4-interacting peptide. SPA4 inhibits the LPS-induced TNF-α cytokine response without effect the cell viability or size .
    SPA4
  • HY-135129
    Dot1L-IN-6

    		Histone Methyltransferase Cancer
    Dot1L-IN-6 is a potent disruptor of telomeric silencing 1-like protein (DOT1L) inhibitor with an IC50 SPA DOT1L of 0.19 nM .
    Dot1L-IN-6
  • HY-130264
    HIF-2α-IN-2

    		HIF/HIF Prolyl-Hydroxylase Cancer
    HIF-2α-IN-2 is a hypoxia-inducible factors (HIF-2α) inhibitor extracted from patent WO2015035223A1, Compound 232, has an IC50 of 16 nM in scintillation proximity assay (SPA) .
    HIF-2α-IN-2
  • HY-P2093A
    S961 TFA

    		Insulin Receptor Metabolic Disease
    S961 TFA is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively .
    S961 TFA
  • HY-109125A
    Amcipatricin L-aspartate

    SPA-S-753; SPA-S-752 L-aspartate

    		 Antibiotic Fungal Infection
    Amcipatricin diaspartate (SPA-S-753) is a semi-synthetic polyene antibiotic, with potent broad-spectrum antifungal activity .
    Amcipatricin L-aspartate
  • HY-RS13613
    SPA17 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    SPA17 Human Pre-designed siRNA Set A contains three designed siRNAs for SPA17 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SPA17 Human Pre-designed siRNA Set A
    SPA17 Human Pre-designed siRNA Set A
  • HY-RS21050
    Spa17 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Spa17 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Spa17 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Spa17 Mouse Pre-designed siRNA Set A
    Spa17 Mouse Pre-designed siRNA Set A
  • HY-172452
    RSV L-protein-6

    		RSV Infection
    RSV L-protein-6 (Compound 19a) is a respiratory syncytial virus polymerase inhibitor, with an IC50 of 13 nM in SPA primer extensions enzymatic assay. RSV L-protein-6 can inhibit RSV replication in Hela cells .
    RSV L-protein-6
  • HY-10555
    AMG-221

    		11β-HSD Metabolic Disease
    AMG-221 is an inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) with a Ki of 12.8 nM in vitro biochemical scintillation proximity assay (SPA) and an IC50 of 10.1 nM in cell-based assays . AMG-221 can be used for the research of type 2 diabetes .
    AMG-221
  • HY-147366
    RBP4 ligand-1

    		Lipocalin Family Metabolic Disease
    RBP4 ligand-1 is a non-retinoid ligands for (RBP4) retinol-binding protein 4. The hRBP4SPA IC50 and RBP4-TTR FRET IC50 values are 0.23±0.11 and 0.13±0.12 μM in the radioligand binding assay and FRET assay, respectively .
    RBP4 ligand-1
  • HY-128338
    CETP-IN-3

    		CETP Cardiovascular Disease
    CETP-IN-3 (Compound 13) is an small molecule inhibitor of the plasma glycoprotein cholesterol ester transfer protein (CETP), elevating HDL-C through inhibition of CETP. CETP-IN-3 for the CETP inhibitory activity in the scintillation proximity (SPA) and whole plasma assay (WPA) with IC50s of 0.002 μM and 0.06 μM, respectively .
    CETP-IN-3
  • HY-RS27568
    Spa17 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others
    Spa17 Rat Pre-designed siRNA Set A contains three designed siRNAs for Spa17 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Spa17 Rat Pre-designed siRNA Set A
    Spa17 Rat Pre-designed siRNA Set A
  • HY-164923
    SPA107

    Hemiasterlin methyl ester

    		 Microtubule/Tubulin Cancer
    SPA107 (Hemiasterlin methyl ester) is a Hemiasterlin (HY-117371) analog. SPA107 inhibits the polymerization of tubulin, exhibits antimitotic activity (IC50 of 0.5 nM) and cytotoxicity in p53 mutated MCF-7 cell with IC50 of 0.5 nM .
    SPA107
  • HY-182942
    PV-DPD-19

    		Bacterial Elastase Infection
    PV-DPD-19 is an autoinducer-2 (AI-2) quorum sensing inhibitor. PV-DPD-19 reduces AI-2 production and inhibits the expression of multiple MSCRAMMs. In co-culture systems with Staphylococcus aureus, PV-DPD-19 decreases the production of pyocyanin and Elastase in Pseudomonas aeruginosa. PV-DPD-19 impairs the adhesion ability of Staphylococcus aureus to lung epithelial cells. PV-DPD-19 inhibits biofilm formation of Pseudomonas aeruginosa (MBIC50 = 27 μg/mL) and Staphylococcus aureus (MBIC50 = 35 μg/mL). PV-DPD-19 shows no cytotoxicity in both in vitro lung epithelial cell models and in vivo Galleria mellonella larva models .
    PV-DPD-19
  • HY-10898R
    SB-674042 (Standard)

    		Reference Standards Orexin Receptor (OX Receptor) Neurological Disease Endocrinology
    SB-674042 (Standard) is the analytical standard of SB-674042 (HY-10898). This product is intended for research and analytical applications. SB-674042 is a potent and selective non-peptide orexin OX1 receptor antagonist (Kd=5.03 nM), exhibits 100-fold selectivity for OX1 over OX2 receptors with IC50 values of 3.76 nM and 531 nM, respectively .
    SB-674042 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: